Long‐term efficacy and safety of cryoballoon ablation of atrial fibrillation: A systematic review and meta‐analysis

Abstract

AbstractBackgroundThis meta‐analysis evaluated long‐term efficacy and safety of cryoballoon ablation (CB) of atrial fibrillation (AF).MethodsPubMed, Cochrane Library, and Web of Science were searched until July 31, 2023, for published works investigating efficacy and safety of CB of AF in which mean/median follow‐up time was not less than 36 months. Safety was assessed by adverse events. Efficacy was assessed by AF recurrence, defined as any atrial arrhythmias lasting more than 30 s.ResultsA total of 19 clinical studies were included. After an average of 58.1 months of follow‐up, the overall AF recurrence rate was about 37%. The predictors of recurrence were duration of AF (HR 1.00; 95% CI [1.00 ∼ 1.01]), early recurrence of atrial fibrillation (HR 3.96; 95%CI [1.12 ∼ 14.02]), left atrial diameter (HR 1.04; 95%CI [1.02 ∼ 1.06]), and persistent AF (HR1.47; 95% CI [1.19 ∼ 1.82]). In terms of safety, the incidence of transient phrenic paralysis (PNP) was the highest, about 3%; followed by vascular complications (about 2%); pseudoaneurysm, permanent PNP, and all‐cause death was (about 1%); and pericardial effusion and stroke / TIA was very low.ConclusionCB is associated with low rates of severe complications and reasonable success rates.